长效卡博特韦/利匹韦林与标准口服抗逆转录病毒治疗的安全性及有效性:系统评价与荟萃分析
该系统评价与荟萃分析纳入6项随机对照试验共2829例HIV感染者,比较长效抗逆转录病毒治疗(LAA)与标准口服治疗(SOT)。LAA在抑制HIV RNA<50拷贝/mL方面非劣于SOT(RD -0.00;95%CI -0.03-0.02;P=0.83;I²=51%;高质量证据),但LAA与更高的耐药性(57%;95%CI 33%-78% vs 9%;95%CI 2%-30%;中等质量证据)及1-4级不良事件风险相关(RR 1.22;95%CI 1.12-1.33;P<0.001;I²=62%;中等质量证据)。
要点
- LAA在HIV RNA<50拷贝/mL抑制上非劣于SOT(RD -0.00;95%CI -0.03-0.02;P=0.83;高质量证据)。
- LAA组耐药百分比合并估计为57%(95%CI 33%-78%),SOT组为9%(95%CI 2%-30%)。
- LAA组1-4级不良事件风险高于SOT(RR 1.22;95%CI 1.12-1.33;P<0.001)。
核心结论
- LAA疗效非劣于SOT,但接受LAA的参与者发生耐药、交叉耐药和不良事件的风险更高。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed和Embase数据库并补充ClinicalTrials.gov及灰色文献,纳入截至2024年6月报告LAA与SOT疗效和/或安全性的随机对照试验(RCT)。
- 共纳入6项RCT,涉及2829例参与者。
- 采用Cochrane RoB 2.0评估偏倚风险,采用GRADE评估证据质量。
主要发现
- LAA在抑制HIV RNA<50拷贝/mL方面非劣于SOT(RD -0.00;95%CI -0.03-0.02;P=0.83;I²=51%;高质量证据)。
- LAA与更高的耐药性相关(百分比合并估计57%;95%CI 33%-78% vs SOT组9%;95%CI 2%-30%;中等质量证据)。
- LAA与更高的1-4级不良事件风险相关(RR 1.22;95%CI 1.12-1.33;P<0.001;I²=62%;中等质量证据)。
关键数值与推荐
- 疗效指标为HIV RNA<50拷贝/mL及HIV RNA≥50拷贝/mL。
- 安全性指标包括不良事件(AEs)、治疗中断、CD4计数、代谢参数和耐药性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2023, there were 39.9 million people living with HIV (PLWH) worldwide and 630 000 deaths related to HIV. New strategies are needed, and long-acting antiretrovirals (LAAs) are now widely considered to have great potential to help end the HIV epidemic. This systematic review and meta-analysis compare the safety and efficacy of LAA versus standard oral treatment (SOT) for HIV. METHODS: PubMed and Embase databases, supplemented by ClinicalTrials.gov and grey literature, were searched. Randomized controlled trials (RCTs) reporting efficacy and/or safety of LAA versus SOT for PLWH until June 2024 were included. Efficacy (HIV RNA < 50 copies/mL) and HIV RNA ≥ 50 copies/mL, adverse events (AEs), treatment discontinuation, CD4 count, metabolic parameters and drug resistance were assessed. Prespecified subgroup analyses were conducted. The risk of bias was assessed with Cochrane RoB 2.0. Certainty of evidence was assessed using GRADE. RESULTS: Six RCTs were eligible for inclusion, involving 2829 participants. LAA was non-inferior to SOT in suppressing HIV RNA < 50 copies/mL [Risk Difference (RD), -0.00; 95% CI, -0.03-0.02; P = 0.83; I2 = 51%; high quality of evidence (QoE)]. LAA was associated with higher drug resistance (percentage pooled estimate, 57%; 95% CI, 33%-78% versus 9%; 95% CI, 2%-30%; moderate QoE) and risk of grade 1-4 AEs than SOT [Risk Ratio (RR), 1.22; 95% CI, 1.12-1.33; P < 0.001; I2 = 62%; moderate QoE]. CONCLUSIONS: LAA has non-inferior efficacy compared to SOT. However, participants receiving LAA were at a higher risk of developing drug resistance, cross-resistance and AEs.
引用
- Manalu SBPS, Perez Navarro A, Fairhead C, et al. Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis. J Antimicrob Chemother. 2025. PMID: 39776187. doi:10.1093/jac/dkae480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。